Boston Scientific is bracing for a challenging earnings report on April 22, 2026, with analysts lowering price targets amid concerns over market conditions and a class action lawsuit alleging misleading statements about its U.S. electrophysiology growth. While projected revenues of $5.19 billion and earnings of $0.80 per share suggest potential growth, the company is dealing with increasing competition, regulatory hurdles related to its merger with Penumbra, and adverse trends negatively impacting procedure volumes. As it navigates these challenges, Boston Scientific faces heightened scrutiny and risks of investor damages.
“The proposal to scrap CMS's add-on payments (like NTAP) for innovative devices would likely mean hospitals face full DRG costs for new tech without extra reimbursement. For $MDT and $BSX, this could slow adoption of high-cost products, hit near-term sales/revenue, and weigh on stocks amid tighter margins.”
“RBC lowers its price target for Boston Scientific Corp to $105, down from $115.”
“According to the most followed narrative, Boston Scientific's fair value of $98.90 sits well above the last close at $64.61, putting a spotlight on how future earnings and cash generation are being modeled.”
“However, you still need to weigh risks such as the added debt from the Penumbra deal, as well as any delays or setbacks in delivering planned integration benefits.”
“The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing new competition entrants that were sapping Boston Scientific's U.S. Electrophysiology market share and thus limiting the Company's growth potential;”
“(3) as a result, Defendants' repeated statements of confidence in the U.S. EP division's growth trajectory, including repeatedly elevated full-year guidance metrics, were materially misleading;”
“According to the lawsuit, during the Class Period, defendants made positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Boston Scientific’s U.S. Electrophysiology segment; notably, that management was aware that the segment’s growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating.”
“Due to defendants’ statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific’s net income miss and underwhelming guidance for the first half of fiscal 2026.”
“Boston Scientific (BSX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.”
“For Boston Scientific, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.11%.”
“The earnings report, which is expected to be released on April 22, might help the stock move higher if these key numbers are better than expectations.”
“On April 7, Joanne Wuensch from Citi reduced the price target on Boston Scientific Corp. (NYSE:BSX) from $98 to $87 while maintaining a Buy rating on the stock.”